

## Literatura:

1. Pelka R. The economic situation of chronic wounds. *Krankenpfl J* 1997; 35(9): 338.
2. Gottrup F., Appelqvist J., Price P. Wyniki kontrolowanych i porównawczych badań na ranami niegojącymi się: zalecenia służące podniesieniu jakości danych w opiece i leczeniu ran. *Leczenie Ran* 2010; 7(1-2): 13-44.
3. Jones RE., Foster DS., Longaker MT. Management of chronic wounds – 2018. *JAMA* 2018; 320: 1481-1482.
4. Potempa M., Jonczyk P., Janerka M., et al.: Rany przewlekłe – epidemiologia i czynniki wpływające na proces gojenia. *Leczenie Ran* 2014; 11.
5. Han G., Ceilley R. Chronic wound healing: a review of current management and treatments. *Adv Ther* 2017; 34: 599-610.
6. Golia S., Kamath ASB., Nirmala AR. A study of superficial surgical site infections in a tertiary care hospital a Bangalore. *Int J Res Med. Sci* 2014; 2: 647-652.
7. Jawień A., Bartoszewicz M., Przondo-Mordarska A., et al.: Wytyczne postępowania miejscowego i ogólnego w ranach objętych procesem infekcji. *Leczenie Ran* 2012; 9(3): 59-75.
8. Dissemmond J., Assadian O., Gerber V., et al.: Classification of wounds at risk and their antimicrobial treatment with polyhexanide: a practice-orientated expert recommendation. *Skin Pharmacol Physiol* 2011; 24: 245–255.
9. Powell C. The Delphi technique: myths and realities. *J Adv Nurs* 2003; 41(4): 376- 382.
10. Patel S. Investigating wound infection. *Wound Essentials* 2010; 5(3): 40-47.
11. Zhao G., Usui ML., Lippman SI., et al.: Biofilms and inflammation in chronic wounds. *Adv Wound Care (New Rochelle)* 2013; 2(7): 389–399.
12. Anderl JN., Zahller J., Roe F., Stewart PS. Role of nutrient limitation and stationary- phase existence in *Klebsiella pneumoniae* biofilm resistance to ampicillin and ciprofloxacin. *Antimicrob Agents Chemother* 2003; 47(4): 1251-6.
13. James GA., Swogger E., Wolcott R., et al.: Biofilms in chronic wounds. *Wound Repair Regen.* 2008; 16(1): 37-44.
14. Sopata M., Jawień A., Mrozikiewicz-Rakowska B., et al.: Wytyczne postępowania miejscowego w ranach niezakażonych, zagrożonych infekcją oraz zakażonych – przegląd dostępnych substancji przeciwdrobnoustrojowych stosowanych w leczeniu ran. *Zalecenia Polskiego Towarzystwa Leczenia Ran. Leczenie ran* 2020; 17 (1): 1-21.
15. Kramer A., Dissemmond J., Kim S., et al.: Consensus on wound antisepsis – update 2017. *Diasence* (online); [http://www.diasence.dk/upload\\_dir/shop/Wound-antiseptics-Consensus-paper-2017.pdf](http://www.diasence.dk/upload_dir/shop/Wound-antiseptics-Consensus-paper-2017.pdf).
16. Levine JM. Dakin’s solution: Past, present, and future. *Adv Skin Wound Care.* 2013; 26 (9): 410-414.
17. Landa-Solis C., Gonzales-Espinosa D., Guzman-Soriano B., et al.: Microcyn: a novel super-oxidized water with neutral pH and disinfectant activity. *J Hosp Infect* 2005; 61 (4): 291-299.
18. Armstrong DG., Bohn G., Glat P. et al.: Expert recommendations for the use of hypochlorous solution: science and clinical application. *Ostomy Wound Manage* 2015; 61 (5 suppl): 4S-18S.
19. Couch KS., Miller C., Clossen LA., et al.: Non-cytotoxic wound bed preparation: vashe hypochlorous acid wound cleansing solution. *Wound Source* (online); [http://www.woundsource.com/sites/default/files/whitepapers/non-cytotoxic\\_wound\\_bed\\_preparation\\_white\\_paper.pdf](http://www.woundsource.com/sites/default/files/whitepapers/non-cytotoxic_wound_bed_preparation_white_paper.pdf).
20. Atkins P., Jones L. *Chemia Ogólna Część cz. Materia, Reakcje* (red. wyd. polskiego: Kuryłowicz J). 1st edn. Wydawnictwo Naukowe PWN, Warszawa, 2004.
21. Kramer A., Dissemmond J., Kim S. et al.: Consensus of Wound Antisepsis; Update 2018, *Skin Pharmacol Physiol* 2018; 31: 28-58.
22. Sakarya S., Gunay N., Karakulak M. et al.: Hypochlorous acid: an ideal wound care agent with powerful microbicidal, antibiofilm, and wound healing potency. *WOUNDS.* 2014; 26 (12): 342-350

23. Wang L., Bassiri M., Najafi R. et al.: Hypochlorous acid as a potential wound care agent. Part I. Stabilized Hypochlorous acid: A component of the inorganic armamentarium of innate immunity. *J Burns Wounds*. 2007.
24. Thorn RMS., Lee SWH., Robinson GM., et al.: Electrochemically activated solutions: evidence for antimicrobial efficacy and applications in healthcare environments. *Eur J Clin Microbiol Infect Dis* 2012; 31: 641-653.
25. Tanaka H., Hirakata Y., Kaku M., et al.: Antimicrobial activity of super oxidized water. *J Hosp Infect* 1996; 34: 43-49.
26. Middleton AM., Chadwick MV., Sanderson JL., Gaya H.: Comparison of a solution of super oxidized water (sterilox) with glutaraldehyde for the disinfection of bronchoscopes, contaminated. *J Hosp Infect* 2000; 45: 278-282.
27. Tanaka H., Hirakata Y., Kaku M., et al.: Antimicrobial activity of super oxidized water. *J Hosp Infect* 1996; 34: 43-49.
28. Aggarwal R., Goel N., Chaudhary U., et al.: Evaluation of microbiocidal activity of superoxidized water on hospital isolates. *Ind J Pathol Microbiol*. 2010; 53: 757-759.
29. Velazquez-Meza ME., Hernandez-Salgado M., Sanchez-Aleman MA. Evaluation of the antimicrobial activity of a super oxidized solution in clinical isolates. *Microbial Drug Resistance* 2015; 21: 367-372.
30. Medina-Tamayo J., Sanchez-Miranda E., Balleza-Tapia H. et al.: Super-oxidized solution inhibits IgE-antigen-induced degranulation and cytokine release in mast cells. *Int Immunopharmacol* 2007; 7 (8): 1013-1024.
31. Meyers C. et al.: Efficacy Testing of HOCl as a Disinfectant for High-Risk HPV, The International Conference on Prevention & Infection Control (ICPIC) 2019 ICPIC Conference, Geneva, Switzerland, September 2019/7/8.
32. Bartoszewicz M., Rygiel A. Biofilm jako podstawowy mechanizm zakażenia miejsca operowanego – metody prewencji w leczeniu miejscowym. *Chirurgia Polska* 2006, 8, 3.
33. Maciejewska M., Bauer M., Dawgul M. Nowoczesne metody zwalczania biofilmu. *Postępy Mikrobiologii* 2016; 55 (1): 3-11.
34. Anderl JN., Zahller J., Roe F., Stewart PS. Role of nutrient limitation and stationary- phase existence in *Klebsiella pneumoniae* biofilm resistance to ampicillin and ciprofloxacin. *Antimicrob Agents Chemother* 2003; 47 (4): 1251-1256.
35. D'Atanasio N., Capezone de Joannon A., Mangano G., et al.: A new acid-oxidizing solution: assessment of its role on methicillin-resistant *Staphylococcus aureus* (MRSA) biofilm morphological change. *Wounds* 2015; 27: 265-273.
36. Sauer K., Thatcher E., Northey R., Gutierrez AA. Neutral super-oxidized solutions are effective in killing *P. aeruginosa* biofilms. *Biofouling* 2009; 25 (1): 45-54.
37. Robson MC. Treating chronic wounds with hypochlorous acid disrupts biofilm. *Today's Wound Clinic*. 2014;8(9):20–21.
38. Lipsky BA., Hoey C. Topical antimicrobial therapy for treating chronic wounds. *Clin Infect Dis* 2009; 49 (10): 1541-1549.
39. Küster I., Kramer A., Bremert T., et al.: Eradication of MRSA skull base osteitis by combined treatment with antibiotics and sinonasal irrigation with sodium hypochlorite. *Eur Arch Otorhinolaryngol* 2016; 273 (7): 1951-1956.
40. Honing HJ: Erfahrungen bei der Anwendung von Octenisept- zur Wundantiseptis. *Hyg Med* 2012; 37: 360–362.
41. Selkon JB, Cherry GW, Wilson JM, Hughes MA. Evaluation of hypochlorous acid washes in the treatment of chronic venous leg ulcers. *J Wound Care* 2006;15 (1): 33-37.
42. Niezgoda JA., Sordi PJ., Hermans MG. Evaluation of Vashe wound therapy in the clinical management of patients with chronic wounds. *Adv Skin Wound Care*. 2010;23(8):352-357.
43. Paola LD., Brocco E., Senesi A., et al.: Super-oxidized solution (SOS) therapy for infected diabetic foot ulcers. *WOUNDS* 2006;18(9):262–270.
44. Piaggessi A. et al.: A randomized controlled trial to examine the efficacy and safety of a new super-oxidized solution for the management of wide postsurgical lesions of the diabetic foot. *Int J Low Extrem Wounds*. 2010;9(1); 10-15.89.
45. Prabhakar KBS. et al.: Comparison of Super-oxidized Solution [HOCl] versus Povidone Iodine in Management of Infected Diabetic Ulcers: Our Experience. *Int Arch Integ Med*. 2016: 3(5); 151-158.90.

46. Mekkawy MM., Kamal AA. Randomized Clinical Trial: The Efficacy of Hypochlorous Acid on Septic Traumatic Wound. *J Ed Prac.* 2014; 5(16); 89-100.
47. Pandey PK., et al.: Outcomes of superoxide solution dressings in surgical wounds: a randomized case control trial. *Int J Biol Med Res.* 2011; 2(4); 965-968.
48. Mohd ARR. [a neutral pH superoxidized solution, HOCl] Irrigation in Reducing Infection of a Median Sternotomy Wound. *Heart Surg Forum.* 2010; 13(4); 228- 232.
49. Gebhart F., Hypochlorous acid eyelid wash reduces bacterial load, *Ophthalmology Times*, November 01, 2016.
50. Gold MH., Andriessen A., Bhatia A., et al.: Topical stabilized hypochlorous acid: The future gold standard for wound care and scar management in dermatologic and plastic surgery procedures. *J Cosmet Dermatol* 2020; 00: 1-8.
51. Méndez-Durán A. Efficacy and safety of the use of superoxidized solution in the prevention of dialysis-related infections. *Dial Transpl.* 2013; 34(4); 160-165.
52. Test HET-CAM (Hen's Egg Test- Chorioallantoic Membrane Test Method), antyseptyków stosowanych miejscowo, przeprowadzony przez Zwierzętarnię Wydziału Farmaceutycznego (Akredytowane Laboratorium przez PCA nr AB 1659) Uniwersytet Medycznego w Łodzi w 2021 r.